Grail’s multi-cancer detection test missed a key trial endpoint, pushing its stock down over 30% in 2026 amid regulatory uncertainty.
Grail (NASDAQ: GRAL) reported its Galleri multi-cancer early detection test failed to meet a primary endpoint in a 142,000-person UK trial, raising doubts about FDA approval. The stock has fallen more than 30% this year as investors reassess its regulatory path and commercial viability.
The test, designed to detect over 50 cancers early, aims to reduce late-stage treatment costs. Grail’s PATHFINDER 2 study in North America and the NHS-Galleri trial in England were pivotal for regulatory and insurer coverage decisions. Missing the endpoint complicates efforts to secure reimbursement and adoption.
Shares have underperformed as investors weigh the setback against long-term potential. The FDA’s stance on the test remains unclear, with no immediate timeline for a decision.